system
A chat on subreddit /r/wallstreetbets
human
What is your perspective on the paper? What do you see the optimal situation being?

gpt
Boys, we don't use SGLT2 inhibitors in T1DM because of the high risk of DKA. So now we have a dual inhibitor. SGLT2 reabsorbs 90% of glucose from urine while SGLT1 takes care of the other 10%. Now we're inhibiting 100% of glucose reuptake (potentially). So tell me how the side effects arent just going to be more amplified and harmful. I wanna buy the calls but my clinical experience says no way.